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Abstract
Background—Endoscopic ablation to treat Barrett’s esophagus (BE) with high-grade dysplasia
(HGD) is associated with a decreased incidence of esophageal adenocarcinoma. Endoscopic spray
cryotherapy (CRYO) demonstrates promising preliminary data.
Objective—To assess the safety and efficacy of CRYO in BE with HGD.
Design—Multicenter, retrospective cohort study.
Setting—Nine academic and community centers; treatment period, 2007 to 2009.
Patients—Subjects with HGD confirmed by 2 pathologists. Previous EMR was allowed if
residual HGD remained.
Interventions—CRYO with follow-up biopsies.
Main Outcome Measurements—Complete eradication of HGD with persistent low-grade
dysplasia, complete eradication of all dysplasia with persistent nondysplastic intestinal metaplasia,
and complete eradication of all intestinal metaplasia.
Results—Ninety-eight subjects (mean age 65.4 years, 83% male) with BE and HGD (mean
length 5.3 cm) underwent 333 treatments (mean 3.4 treatments per subject). There were no
esophageal perforations. Strictures developed in 3 subjects. Two subjects reported severe chest
pain managed with oral narcotics. One subject was hospitalized for bright red blood per rectum.
Sixty subjects had completed all planned CRYO treatments and were included in the efficacy
analysis. Fifty-eight subjects (97%) had complete eradication of HGD, 52 (87%) had complete
eradication of all dysplasia with persistent nondysplastic intestinal metaplasia, and 34 (57%) had
complete eradication of all intestinal metaplasia. Subsquamous BE was found in 2 subjects (3%).
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Limitations—Nonrandomized, retrospective study with no control group, short follow-up (10.5
months), lack of centralized pathology, and use of surrogate outcome for decreased cancer risk.
Conclusions—CRYO is a safe and well-tolerated therapy for BE and HGD. Short-term results
suggest that CRYO is highly effective in eradicating HGD.
Barrett’s esophagus (BE) is a metaplastic change in the lining of the esophagus from the
normal squamous lining to specialized columnar epithelium. This change, thought to be
caused by injury from chronic reflux disease, is associated with a 40- to 120-fold increase in
the risk of esophageal adenocarcinoma.1,2 When BE does progress, it seems to do so
through a series of changes from nondysplastic to low-grade dysplasia (LGD) to high-grade
dysplasia (HGD) to cancer. Although the risk of cancer in patients with nondysplastic
disease and LGD seems to be less than 1% per patient-year,3,4 that risk increases
substantially with HGD,5,6 making an intervention desirable to a large proportion of
patients.
Surgical esophagectomy, the traditional intervention offered to subjects with BE and HGD,
is associated with substantial morbidity and some mortality.7 Additionally, because most
subjects diagnosed with HGD are found to have the condition later in life, many are not
surgical candidates. Therefore, investigators have developed a variety of endoscopic
interventions designed to eradicate HGD and induce reversion to squamous epithelium while
leaving the esophagus intact. All of these therapies take advantage of the seminal
observation that rigorous acid suppression combined with BE cell destruction usually results
in partial or full regeneration of squamous epithelium.8 Successful regeneration of squamous
epithelium seems to be associated with a decreased risk of adenocarcinoma of the
esophagus.5,6 Endoscopic therapy may be preceded by EMR of nodular epithelium.
Alternatively, stepwise radical mucosal resection may be used to remove all metaplastic
tissue.9
Endoscopic spray cryotherapy (CRYO) using liquid nitrogen is a novel method of
destruction of BE tissue. Initial reports suggest that this therapy is well tolerated and
effective in inducing neosquamous epithelium in subjects with BE.10,11 This retrospective
study reports the safety and efficacy of CRYO in subjects with BE and HGD.
METHODS
Study design and subjects
We performed a retrospective analysis of consecutive subjects with BE and HGD
undergoing CRYO at 9 sites in the United States. Subjects with unifocal or multifocal HGD
of any length were eligible. All pathological specimens demonstrating HGD were confirmed
with a second histological analysis by an expert pathologist. Previous EMR or other
previous endoscopic therapy was allowed if the results demonstrated no evidence of residual
adenocarcinoma and residual HGD was present in the tubular esophagus at commencement
of CRYO. CRYO was performed with the intent to eradicate all BE. Each site participating
in the study offers comprehensive therapy for BE. All subjects signed informed consent for
the endoscopic procedures, and the protocol for retrospective, anonymous collection of these
data was reviewed and approved by the institutional review boards of all participating
centers.
Take-Home Message
• Multiple methods have been described to perform endoscopic ablative therapy
in the setting of Barrett’s esophagus. Endoscopic cryotherapy, in this
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preliminary report, seems safe and efficacious in downgrading dysplasia in
subjects with Barrett’s esophagus and high-grade dysplasia.
Study intervention
Subjects were sedated by using either propofol (23% of procedures) or a combination of
narcotic and benzodiazepine (77% of procedures). Standard diagnostic upper endoscopy was
performed. Subjects were then treated with the CSA cryotherapy system (CSA Medical,
Baltimore, Md). This system is a noncontact method of cryotherapy, applying medical-grade
−196°C liquid nitrogen by using a low-pressure, disposable 7F spray catheter directly to the
tissue targeted for treatment at a cooling rate of 25 W. The system enables the physician to
control the duration of the cryogen spray to the selected site by depressing a foot pedal.
Before the administration of the liquid nitrogen, a duallumen decompression tube was
placed in the gastric antrum to evacuate nitrogen gas by both passive venting and active
suction (Fig. 1A). To administer the liquid nitrogen, a polyamide catheter was introduced
through the working channel of an adult endoscope and positioned 3 to 4 mm beyond the
distal tip of the endoscope (or at the distal edge of a clear, friction-fit cap, if used). Gas flow
was initiated by depressing a foot pedal. The treatment area was limited to 2 to 3 cm of
mucosa in a hemicircumferential or one third circumferential pattern so that freezing could
be maintained without reperfusion during the treatment. In situations in which the
decompression tube blocked the flow of cryogen onto selected sites, the endoscope tip was
used to gently reposition the tube out of the path of the spray. The endoscopist monitored the
endoscopic appearance of the tissue, and when white frost was noted in the treatment area, a
timer was actuated to track the freeze time (Fig. 1B). Treatment dosimetry (the duration of
the tissue freeze time in seconds and the number of cycles in which the target site was frozen
and thawed) was either 2 cycles of 20 seconds or 4 cycles of 10 seconds. During the
intervening thaw cycles, the tissue reperfused, with return to its normal salmon color.
Monitoring of the abdomen was performed by a nurse or technician for any signs of
abdominal distention. Typical initial treatments involved 3 to 5 treatment sites.
All procedures were performed on an outpatient basis. Subjects were discharged with
acetaminophen for pain control. Follow-up procedures were performed at 2- to 3-month
intervals until eradication of BE was confirmed by both histological and endoscopic findings
or until the clinician and/or patient opted to halt treatment for clinical reasons, including
worsening comorbidities, disease progression, and patient preference.
Biopsy technique and histological analysis
At follow-up endoscopy sessions, biopsies were performed every 1 to 2 cm in 4 quadrants.
Each endoscopic biopsy level specimen was placed in a separate container for analysis.
Tissue was fixed in formalin and subsequently embedded in paraffin. Tissue was stained
with hematoxylin and eosin. Biopsy specimens were interpreted at the home institution by
pathologists expert in the assessment of BE. Any reading of HGD or cancer was confirmed
by a second pathologist. Biopsy specimens were graded by using standardized criteria for
BE, requiring the presence of goblet cells for the diagnosis.12
Data collection and analysis
All participating sites use electronic medical records. For each subject, data of the following
variables were collected: age, sex, initial length of the BE, EMR history, any complications
of the ablative therapy, and the results of the ablative therapy. The potential results of
ablative therapy included progression to esophageal adenocarcinoma, continued presence of
HGD, complete eradication of HGD with persistent LGD, eradication of all dysplasia with
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persistent nondysplastic intestinal metaplasia, and eradication of all intestinal metaplasia.
Potential complications assessed included perforation, stricture requiring dilation, bleeding
requiring transfusion, and pain requiring narcotic analgesia or hospitalization. Stricture was
defined as an endoscopically evident narrowing of the esophagus, with or without the patient
reporting dysphagia. Additionally, for each diagnostic or therapeutic procedure, we recorded
the total procedure time, sedation used, performance of any endoscopic biopsies, and
histology results.
For purposes of this analysis, we divided the cohort into 2 groups. For the safety analysis, all
subjects and all treatments were analyzed. For the efficacy analysis, we included subjects
who had at least 1 postablation endoscopy with biopsies and for whom no further CRYO
treatment was planned.
For continuous variables such as age and medication dose, mean and standard deviation
(SD) are reported. For categorical data, proportions are reported. To compare responders
with nonresponders, the Fisher exact and χ2 tests were used. All tests of significance were 2
tailed, and α values <.05 were considered significant.
RESULTS
A total of 98 subjects fulfilled criteria and were included in the study. Mean (SD) age was
65.4 (10) years, and 83% were male (Table 1). The baseline mean (SD) endoscopic length of
BE was 5.3 (3.2) cm. Before enrollment in the study, 1 (1%) subject had undergone Nissen
fundoplication. Two (2%) subjects were status post partial esophagectomy for HGD with
recurrent HGD in the esophageal remnant. Fourteen (14%) subjects were status post some
form of previous unsuccessful ablative therapy (2% argon plasma coagulation, 6%
radiofrequency ablation [RFA], 6% photodynamic therapy [PDT]), and 22 (22%) subjects
were status post EMR. EUS was performed on 71% of subjects before therapy to assess for
evidence of locoregional or celiac lymphadenopathy.
Of the 98 subjects enrolled in the study, 60 had completed all planned CRYO treatments,
with the remainder still undergoing planned therapy. The baseline characteristics of the
subjects who had completed therapy did not differ significantly from those still undergoing
therapy (Table 1).
Efficacy analysis
Figure 2 demonstrates the efficacy results of the study. Of the 60 patients who completed all
planned CRYO treatments, 58 (97%) had complete eradication of HGD, 52 (87%) had
complete eradication of intestinal dysplasia, and 34 (57%) had complete eradication of
intestinal metaplasia. These subjects underwent a mean (SD) of 4.0 (2.9) treatments.
Subjects completing CRYO treatments have been followed for a mean (SD) of 10.5 (8.3)
months after completing CRYO with 3- to 6-month surveillance endoscopies per the
institutions’ postablation protocols. Subsquamous BE was found on biopsy specimens in 2
(3%) subjects (Fig. 3).
Safety analysis
A total of 333 treatments were performed in the 98 subjects enrolled in the study (mean 3.4
treatments per subject), all on an outpatient basis (Table 2). There were no serious adverse
events or perforations. Strictures (3% of patients, 1% of treatments) developed in 3 subjects,
and all underwent successful endoscopic dilation (2, 3, and 3 dilations, respectively, for
symptom resolution). Two subjects reported severe chest discomfort after the procedure (2%
of patients, 1% of treatments) and were successfully managed with oral narcotics on an
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outpatient basis. There was disease progression in 1 patient despite treatment. In this patient,
a nodule was noted at the gastroesophageal junction at the second planned CRYO treatment.
EMR was performed, with pathology findings of intramucosal adenocarcinoma. This subject
underwent successful esophagectomy and is cancer free 1 year later. One subject required
hospitalization post-procedure for bright red blood per rectum. This subject was admitted
and observed overnight with no significant change in hematocrit or additional evaluation
performed.
DISCUSSION
Endoscopic ablation to eradicate HGD and induce reversion to squamous epithelium is a
viable, esophagus-sparing treatment option for patients with BE and HGD. Multiple
methods of endoscopic ablation have been developed. Each method differs in mechanism
and effectiveness of ablation, side effects, and cost. Our retrospective analysis of subjects
with HGD treated with CRYO at 9 institutions, the largest reported experience with this
technique to date, suggests that CRYO is associated with a favorable side effect profile and
leads to reversion to squamous epithelium in the majority of treated subjects. We found that
the therapy was well tolerated, with only 1 hospitalization after 333 treatments and a
stricture rate of 3%.
Previous data on endoscopic cryotherapy using either liquid nitrogen or carbon dioxide
suggest that the treatment is effective in downgrading dysplasia and causing reversion of
intestinal metaplasia to neosquamous epithelium. In 2005, Johnston et al10 reported a pilot
single-center study of CRYO in 11 subjects with metaplasia and/or dysplasia. Nine subjects
completed the study, and all had complete eradication of both metaplasia and dysplasia at
the end of treatment. Therapy was well tolerated, and there were no reports of perforations,
strictures, or severe chest pain. In 2008, Canto et al13 reported in abstract form a single-
center experience of carbon dioxide spray cryotherapy in 33 subjects with HGD and/or
intramucosal carcinoma. EMR and/or PDT failed in all subjects, and they were considered at
high risk of esophagectomy. At the time that the data were reported, the study was ongoing
and a mean of 3 treatments per subject had been performed. They reported a preliminary
72% mean reduction in BE in subjects still undergoing treatment. Therapy was well
tolerated, and there were no reports of perforations, strictures, or severe chest pain.
In 2009, Dumot et al14 reported a single-center study of CRYO in 30 subjects with HGD
and/or intramucosal carcinoma. All subjects were considered at high risk of esophagectomy
or had refused surgical intervention. They found that 90% of the subjects treated had a
downgrading of pathology stage. In this study, 3 (10%) subjects reported severe chest pain
and 3 (10%) had strictures requiring dilation. Also, in this series, a gastric perforation
developed during treatment as a result of excessive gastric distention in a patient with
Marfan syndrome. Concerns of barotrauma of the stomach resulted in the development of a
dual-lumen orogastric decompression study, with both active and passive venting of gas to
prevent overdistention. These data were also included in a multicenter study of CRYO by
Greenwald et al.11 In this 4-center study, 77 subjects with metaplasia, LGD, HGD,
intramucosal carcinoma, invasive carcinoma, or severe squamous dysplasia were treated
with CRYO therapy. Of the 17 subjects with HGD who had completed therapy, 94% had
complete eradication of HGD, 88% had complete eradication of dysplasia, and 53% had
complete eradication of intestinal metaplasia. Overall, a total of 323 treatments were
performed in the cohort, with strictures requiring dilation developing in 3 subjects and 3.7%
reporting moderate or severe chest discomfort.
Given the preliminary nature of the data regarding the efficacy of CRYO in the treatment of
dysplastic BE, it is challenging currently to compare this modality with other available
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choices for ablative therapy. Our preliminary safety data compare favorably with those of
PDT. Our stricture rate is far lower than that reported in case series15 and in the randomized,
controlled trial of PDT versus medical therapy performed by Overholt et al.6 Additionally,
rates for complete clearance of intestinal metaplasia in this study are higher than those
reported with PDT.6 How does CRYO compare with RFA? RFA has an excellent safety
profile, similar to that found in this study.5,16 Although the 74% rate of complete eradication
of intestinal metaplasia (82% per protocol) reported in the HGD arm of a recent RFA sham-
controlled, randomized trial5 is higher than the 57% rate reported here, the subjects in the
RFA trial all had BE of less than 8 cm, were treatment naïve, and fulfilled other exclusion
criteria not present in the current study. Ganz et al17 reported outcomes of 142 subjects with
HGD treated with RFA as part of the RFA HGD registry. This cohort is most comparable to
that in the present study because it was retrospective in nature, had few exclusion criteria,
and was collected from multiple centers. Interestingly, in this registry, complete eradication
of intestinal metaplasia occurred in 54% of subjects, a figure virtually identical to the 57%
reported here. One potential advantage to CRYO is that tissue apposition to a probe or
device is not needed for efficacy. Therefore, such a spray application might have special
utility when firm tissue contact is either unattainable or made difficult because of previous
endoscopic therapy such as EMR.
The strengths of our study include an analysis of data obtained from both community and
academic centers and the inclusion of a large number of patients with HGD. Study
definitions were standardized, and rigorous, histology-based outcomes were used. Our study
also had several limitations. We used a retrospective cohort with short-term follow-up (10.5
months), which is subject to bias. The effect of ablative therapy can be exaggerated in
observational studies by the combined factors of spontaneous regression, sampling error,
and variability of histological interpretation of biopsy specimens.18 Although all the
participating centers are expert in the care of subjects with BE, pathology from the centers
was not reviewed by a central laboratory. Our primary outcome in this study, eradication of
intestinal dysplasia and metaplasia, was used as a surrogate outcome marker for decreased
cancer risk, and data linking the two are sparse.5,6 As with all ablative therapies that do not
recover a specimen for histological evaluation, the potential for understaging an invasive
adenocarcinoma exists. Although the risk of submucosal cancer seems low in appropriately
chosen subjects with HGD,9 better definition of this risk is necessary.
In conclusion, CRYO is a safe and well-tolerated therapy for subjects with BE and HGD.
Short-term results suggest that the therapy is effective in eradicating HGD and that a
majority of subjects will have complete eradication of all intestinal metaplasia as well.
Further analysis of this cohort will determine the durability of the changes reported here as
well as the cancer risk in subjects treated with this modality.
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A, Dual-channel decompression tube in place, as seen through the endoscope with a friction-
fit cap before administration of liquid nitrogen. B, White frost demonstrated in the distal
esophagus, signaling the freeze time.
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Efficacy cohort analysis: percentage achieving complete eradication.
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TABLE 2
Procedure variables and adverse events
Total no. treatments 333
Perforation, no. (%)* 0(0)
Stricture, no. (%)* 3 (3)
Severe pain, no. (%)* 2 (2)
Hospital admission, no. (%)* 1 (1)





Percentages are per patient.
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